OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2005
Business Overview: The company develops, manufactures, and markets oral specimen collection devices, diagnostic products (infectious disease and substance abuse testing), and cryosurgical medical devices. Key products include the OraQuick rapid HIV test, Intercept oral fluid drug testing, and Freeze Off/Histofreezer cryosurgical systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 28% year-over-year, driven by a 54% surge in infectious disease testing sales (primarily OraQuick ADVANCE) and a 33% increase in substance abuse testing sales.
• Profitability Turnaround: The company reported a net income of $1.6 million, a reversal from a net loss of $162,000 in the prior year quarter. Operating income improved from a loss of $326,000 to a profit of $1.2 million.
• Expense Management: Research and development expenses decreased 32% due to lower staffing costs and the closure of the Oregon facility. However, General and Administrative expenses increased 49% due to legal fees related to patent litigation and stock-based compensation amortization.
• Market Shifts: Sales in the insurance risk assessment market declined 7% due to competitive pressure from customer-developed "home-brew" assays.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Product Launches: Management expects continued growth in the OraQuick ADVANCE HIV test and Intercept drug testing lines. The company aims to obtain CE marking for OraQuick ADVANCE by summer 2005 to facilitate European sales.
• Strategic Partnerships: A new agreement with Abbott Laboratories appoints them as the exclusive distributor for the U.S. hospital market for OraQuick ADVANCE. The company retains rights to public health and government markets.
• Capital Expenditures: Capital expenditures are anticipated to increase to approximately $3.2 million in 2005 for manufacturing and R&D equipment.
• Accounting Changes: Adoption of SFAS No. 123R (Share-Based Payment) is expected to reduce net income by approximately $900,000 for the period if applied prospectively.

Risks and Contingencies

• Litigation: The company is engaged in patent infringement litigation against Schering-Plough regarding cryosurgical wart removal technology. A trial is expected in 2005.
• Customer Concentration: Two customers accounted for approximately 37% of total revenues in Q1 2005 (Medtech at 25% and Lab One at 12%).
• Regulatory Dependence: The company relies on sole-source providers for critical components and requires FDA approvals for product changes. Delays could disrupt sales.
• Product Cannibalization: Increased sales of the OraQuick rapid test may negatively impact sales of the OraSure collection device as customers switch to the all-in-one rapid test.

Investor Verification Checklist

• Customer Concentration: Verify the financial stability of Medtech (25% of revenue) and Lab One (12% of revenue), as their performance heavily influences results.
• Litigation Status: Monitor the progress of the Schering-Plough patent lawsuit, as legal fees are already impacting G&A expenses and a loss could be material.
• Regulatory Approvals: Track the timeline for CE marking of OraQuick ADVANCE for European expansion and the status of the UP link 510(k) clearance.
• Inventory Valuation: Review inventory levels given the expiration dating of diagnostic products and the history of write-offs ($839k in 2004).
• Debt Covenants: Confirm continued compliance with the Comerica Bank Credit Facility covenants (quick ratio, liquidity, tangible net worth).